London FTSE 100 LIVE: Blue-chips nose 59 points lower amid heightened geopolitical worries
Advertisement Go to Proactive UK Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Growth stocks coverage continues on proactiveinvestors.com
The Markets
by Proactive
Proactive UK has moved.
Growth stocks coverage continues on .com
Economics UK unemployment holds at 4.9% as benefit claims jump
Retail & consumer Wickes reports sharp pick-up in trading as shoppers return
New York Wall Street closes 150 points lower as AI jitters and Treasury yields weigh
Tuesday 15 September
Today’s Edition
Advertisement Go to Proactive UK Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Growth stocks coverage continues on proactiveinvestors.com
The Markets
by Proactive
Proactive UK has moved.
Growth stocks coverage continues on .com
Market Reports
All market reportsLondon: FTSE 100 LIVE: Blue-chips nose 59 points lower amid heightened geopolitical worries
New York: Wall Street closes 150 points lower as AI jitters and Treasury yields weigh
Bitcoin: Bitcoin climbs toward $78,000 as traders brace for Fed decision
Mining: Gold slips below $4,300 as Fed rate hike bets strengthen
More today
Berenberg lifts Antofagasta to buy after copper sell-off opens the door
Analysts see 16% upside in the Chilean miner, calling the recent share weakness a compelling entry point
What brokers say
All broker viewsFinance: Bank of England set for hawkish hold as inflation risks resurface, says UBS
Mining: Berenberg lifts Antofagasta to buy after copper sell-off opens the door
Mining: Citi sticks with $15,000 copper target as bullish forces outweigh US tariff risk
Health: Roche sequencer poses little threat to Oxford Nanopore, expert tells Citi
Citi sticks with $15,000 copper target as bullish forces outweigh US tariff risk
The bank sees structural, cyclical and strategic tailwinds carrying the metal higher into 2027, offsetting American trade headwinds
Roche sequencer poses little threat to Oxford Nanopore, expert tells Citi
A genomics specialist hosted by the bank backs Oxford Nanopore's position and rates it above rival Pacific Biosciences
AstraZeneca breast cancer drug fails trial but Citi keeps buy rating
Analysts say the SERENA-4 setback for camizestrant does little damage and maintain their £178 target price on the shares
Advertisement Go to Proactive UK Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Growth stocks coverage continues on proactiveinvestors.com
The Markets
by Proactive
Proactive UK has moved.
Growth stocks coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Growth stocks coverage continues on .com
Tuesday 15 September
Today’s Edition
- London / FTSE 100 LIVE: Blue-chips nose 59 points lower amid heightened geopolitical worries
- Economics / UK unemployment holds at 4.9% as benefit claims jump
- Retail & consumer / Wickes reports sharp pick-up in trading as shoppers return
- New York / Wall Street closes 150 points lower as AI jitters and Treasury yields weigh
Wickes shares jump 8% as Q3 pick-up eclipses soft first half
Trustpilot shares tumble 16% as tax and buyback blunders overshadow solid interims
UK pay growth cools to 3.9% as Bank of England weighs rate decision
TotalEnergies strikes oil exploration partnership with French AI firm Mistral
Kier lifts sights for the year ahead as order book hits record high
Most Read
- Lloyds tipped as frontrunner to buy Aldermore in £1.4 billion deal
- FTSE 100 LIVE: UK blue-chips kick on as Wall Street slumps into red
- Capita's pension recovery: progress banked, but the real test is winning work
- FTSE 100 Live: London shares climb as Wall Street opens higher after US CPI report
- FTSE 100 LIVE: Blue-chips nose 59 points lower amid heightened geopolitical worries
- Persimmon and Barratt Redrow are UBS top picks as housebuilders await recovery
- FTSE 100 Live: FTSE 100 slides as ECB raises rates and oil surges above $105
- Oil prices ease from highs but Middle East risks keep $120 in view
- GlobalData shares fall 17% as growth push squeezes margins
- Ilika, Genflow Biosciences, EnergyPathways, Ariana Resources, Tertiary Minerals, Light Science Technologies - Small Cap Week in Review
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Growth stocks coverage continues on .com
GSK strikes deal worth up to $750 million for cancer drug
FTSE 100 LIVE: UK blue-chips kick on as Wall Street slumps into red
Capita's pension recovery: progress banked, but the real test is winning work
Bank of England set for hawkish hold as inflation risks resurface, says UBS
Berenberg lifts Antofagasta to buy after copper sell-off opens the door
Analysts see 16% upside in the Chilean miner, calling the recent share weakness a compelling entry point
Market Reports
London: FTSE 100 LIVE: Blue-chips nose 59 points lower amid heightened geopolitical worries
New York: Wall Street closes 150 points lower as AI jitters and Treasury yields weigh
Bitcoin: Bitcoin climbs toward $78,000 as traders brace for Fed decision
Mining: Gold slips below $4,300 as Fed rate hike bets strengthen
Big caps
- Berkeley warns buyers may hold off until Budget as market uncertainty deepens
- Oracle beats on top and bottom lines as cloud revenue surges
- AstraZeneca's $5bn drug promise is no 'buy' signal for Deutsche
- Apple unveils iPhone Duo, its first foldable, alongside a full smartphone and watch refresh
- FeverTree posts strong first-half profit as US growth accelerates
- Apple unveils first foldable iPhone at first Ternus keynote
Citi sticks with $15,000 copper target as bullish forces outweigh US tariff risk
The bank sees structural, cyclical and strategic tailwinds carrying the metal higher into 2027, offsetting American trade headwinds
Roche sequencer poses little threat to Oxford Nanopore, expert tells Citi
A genomics specialist hosted by the bank backs Oxford Nanopore's position and rates it above rival Pacific Biosciences
Bitcoin climbs toward $78,000 as traders brace for Fed decision
AstraZeneca breast cancer drug fails trial but Citi keeps buy rating
Analysts say the SERENA-4 setback for camizestrant does little damage and maintain their £178 target price on the shares
Gold slips below $4,300 as Fed rate hike bets strengthen
What brokers say
Finance: Bank of England set for hawkish hold as inflation risks resurface, says UBS
Mining: Berenberg lifts Antofagasta to buy after copper sell-off opens the door
Mining: Citi sticks with $15,000 copper target as bullish forces outweigh US tariff risk
Health: Roche sequencer poses little threat to Oxford Nanopore, expert tells Citi
Global stocks
- TotalEnergies strikes oil exploration partnership with French AI firm Mistral
- Nvidia CEO's 'eye-popping' 70% growth pitch might not be as wild as it sounds, let's explore why
- Small cap wrap: Ocean Power Technologies, Domestic Metals, Purepoint Uranium...
- Apple, Compass Pathways, Aritzia and more analyst calls of the week
- Frank Talk: Copper supply faces first annual decline since 2017
- Market movers: Dell, Kroger, Oklo...
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Growth stocks coverage continues on .com